NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to Radiation Therapy for Localized Pancreatic Cancer

Phase 1

Recruiting

Conditions: Locally Advanced Pancreatic Adenocarcinoma
Stage III Pancreatic Cancer AJCC v8

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Radiation: Hypofractionated Radiation Therapy
Procedure: Magnetic Resonance Imaging
Drug: Peposertib
Other: Placebo Administration

First Posted Date: 2019-11-21

Last Posted Date: 2025-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 98

Registration Number: NCT04172532

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸
City of Hope at Irvine Lennar, Irvine, California, United States

and more 39 locations

VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)

Phase 2

Completed

Conditions: Colorectal Cancer With Hepatic Metastases
Metastatic Colorectal Cancer
Colorectal Neoplasms
Colorectal Carcinoma
Colorectal Tumors

Interventions: Biological: Vascular Biogenics (VB)-111
Drug: Nivolumab

First Posted Date: 2019-11-18

Last Posted Date: 2023-11-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 14

Registration Number: NCT04166383

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

Phase 3

Suspended

Conditions: Low Grade Astrocytoma
Metastatic Low Grade Glioma
Low Grade Glioma
Metastatic Low Grade Astrocytoma

Interventions: Procedure: Biospecimen Collection
Drug: Carboplatin
Procedure: Magnetic Resonance Imaging
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Selumetinib Sulfate
Drug: Vincristine Sulfate

First Posted Date: 2019-11-18

Last Posted Date: 2025-06-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 220

Registration Number: NCT04166409

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Banner Children's at Desert, Mesa, Arizona, United States
🇺🇸
Phoenix Childrens Hospital, Phoenix, Arizona, United States

and more 126 locations

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Phase 2

Recruiting

Conditions: Bladder Flat Urothelial Carcinoma In Situ
Non-Muscle Invasive Bladder Urothelial Carcinoma
Stage 0a Bladder Cancer AJCC v8
Stage 0is Bladder Cancer AJCC v8
Stage I Bladder Cancer AJCC v8

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Cystoscopy
Drug: Gemcitabine Hydrochloride
Procedure: Magnetic Resonance Imaging
Biological: Pembrolizumab
Procedure: Transurethral Resection of Bladder Tumor

First Posted Date: 2019-11-15

Last Posted Date: 2025-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 161

Registration Number: NCT04164082

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States

and more 389 locations

T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma

Phase 1

Terminated

Conditions: Lymphoma, Non-hodgkins
Lymphoma, B-Cell
B-Cell Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia

Interventions: Biological: Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2019-11-12

Last Posted Date: 2022-02-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 2

Registration Number: NCT04160195

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma

Phase 2

Terminated

Conditions: Clear-Cell Renal Carcinoma

Interventions: Drug: rhIL-15
Biological: Avelumab

First Posted Date: 2019-11-04

Last Posted Date: 2022-05-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 2

Registration Number: NCT04150562

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer

Recruiting

Conditions: Hepatocellular Carcinoma
Cholangiocarcinoma
Liver Cancer

First Posted Date: 2019-10-30

Last Posted Date: 2025-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 500

Registration Number: NCT04145141

Locations: 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
Georgetown University, Washington, District of Columbia, United States
🇺🇸
University of California, San Diego (UCSD), La Jolla, California, United States

and more 4 locations

A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden

Phase 2

Suspended

Conditions: Astrocytoma, IDH-Mutant, Grade 4
Glioblastoma, IDH-Wildtype
Secondary Glioblastoma
Diffuse Glioma

Interventions: Biological: Ipilimumab
Procedure: Magnetic Resonance Imaging
Biological: Nivolumab

First Posted Date: 2019-10-30

Last Posted Date: 2025-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT04145115

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Longmont United Hospital, Longmont, Colorado, United States
🇺🇸
Cancer Center of Kansas - Newton, Newton, Kansas, United States

and more 413 locations

Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma

Phase 1

Withdrawn

Conditions: Unresectable NUT Carcinoma
Metastatic NUT Carcinoma

Interventions: Drug: Cisplatin
Drug: Etoposide
Drug: Etoposide Phosphate
Drug: Molibresib
Drug: Molibresib Besylate

First Posted Date: 2019-10-04

Last Posted Date: 2020-09-28

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT04116359

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

Phase 1

Terminated

Conditions: Anatomic Stage IV Breast Cancer AJCC v8
HER2-Positive Breast Carcinoma
Metastatic Breast Carcinoma

Interventions: Drug: Copanlisib
Biological: Trastuzumab
Biological: Pertuzumab

First Posted Date: 2019-09-30

Last Posted Date: 2024-06-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 2

Registration Number: NCT04108858

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
UCHealth University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy